A Review on Regional Approaches to Disease Burden, Monitoring, and Control of Diabetes Mellitus and Hypertension Comorbidity

Abstract

Diabetes mellitus and hypertension represent two of the most prevalent non-communicable diseases globally, and their co-occurrence is so frequent that it now constitutes a distinct cardiometabolic syndrome with multiplicative vascular risk. This review synthesizes the global epidemiology of the diabetes-hypertension comorbidity, examines regional patterns of disease burden, monitoring, and control, and analyses the pathological linkages that amplify target organ damage. A structured literature search of PubMed, Google Scholar, NCBI and Web of Science was conducted, concentrating on peer-reviewed articles published between 2020 and 2026. The evidence reveals profound regional disparities in both the prevalence and the management of the dual condition. Sub-Saharan Africa, South Asia, and parts of Latin America carry a disproportionate and rapidly rising burden, yet glycaemic and blood pressure control rates in these regions remain unacceptably low. Integrated pharmacological management, anchored by renin-angiotensin-aldosterone system blockers and increasingly by sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, has transformed outcomes in well-resourced settings but remains inaccessible where the need is greatest. Equally important are structured lifestyle interventions, pharmacist-led support, task-sharing, and culturally adapted patient education. Without these measures, the global community will fail to stem the tide of cardiovascular and renal complications driven by this intertwined epidemic.